Fixed dose combinations: A formulary decision guide

Esba, Laila Carolina Abu; Yousef, Consuela Cheriece; Ismail, Sherine; Halim, Murtada; Almodaimegh, Hind; Alabdulkarim, Hana; Alhowimel, Mansour

doi:10.1016/j.hlpt.2021.02.006

Cited by 6 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, even when using generic formulations, FDC is less expensive than free-drug combinations of the same medicines ( Tsioufis and Thomopoulos, 2017 ). Due to the advantages brought by FDC, not only does it decrease the non-compliance rate of medication regimens, but it also assists physicians with prescriptions based on current guidelines ( Esba et al, 2021 ). In 2019, FDC drugs in antihypertensive medications were added to the WHO Model List of Essential Medicines ( Organization, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review

Dat,

Tu,

Thu

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Uncontrolled blood pressure is a major risk factor for cardiovascular diseases. Fixed-dose combination (FDC) therapy offers a promising approach to addressing this challenge by providing a convenient single-tablet solution that enhances the effectiveness of blood pressure control. In our systematic review, we assess the effectiveness of perindopril/amlodipine FDC in managing blood pressure.Methods: We conducted a comprehensive search across four primary electronic databases, namely, PubMed, Virtual Health Library (VHL), Global Health Library (GHL), and Google Scholar, as of 8 February 2022. Additionally, we performed a manual search to find relevant articles. The quality of the selected articles was evaluated using the Study Quality Assessment Tools (SQAT) checklist from the National Institute of Health and the ROB2 tool from Cochrane.Results: Our systematic review included 17 eligible articles. The findings show that the use of perindopril/amlodipine FDC significantly lowers blood pressure and enhances the quality of blood pressure control. Compared to the comparison group, the perindopril/amlodipine combination tablet resulted in a higher rate of blood pressure response and normalization. Importantly, perindopril/amlodipine FDC contributes to improved patient adherence with minimal side effects. However, studies conducted to date have not provided assessments of the cost-effectiveness of perindopril/amlodipine FDC.Conclusion: In summary, our analysis confirms the effectiveness of perindopril/amlodipine FDC in lowering blood pressure, with combination therapy outperforming monotherapy and placebo. Although mild adverse reactions were observed in a small subset of participants, cost-effectiveness assessments for this treatment remain lacking in the literature.

show abstract

Section: Introductionmentioning

confidence: 99%

Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review

Dat,

Tu,

Thu

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Frontiers in Pharmacology | www.frontiersin.org October 2021 | Volume 12 | Article 730257 9 Esba et al, 2021). Several such multicomponent drugs have been launched for diverse indications, but clinicians might still prefer prescribing combinations of existing monotherapies that may offer greater dose flexibility and lower cost treatment, particularly in the case of generic drugs.…”

Section: Drug Combinationmentioning

confidence: 99%

“…However, the benefits of this approach are often compromised by poor patient compliance. In the last ∼20 years, there have been attempted moves toward multicomponent drugs whereby two or more agents are co-formulated in a single tablet in a fixed-dose combination to make dosing regimens simpler, thereby improving patient compliance ( Morphy and Rankovic, 2005 ; Wertheimer, 2013 ; Esba et al, 2021 ). Several such multicomponent drugs have been launched for diverse indications, but clinicians might still prefer prescribing combinations of existing monotherapies that may offer greater dose flexibility and lower cost treatment, particularly in the case of generic drugs.…”

Section: Is Multi-target Combination Therapy (“Rational Polytherapy”) Of Epilepsy More Effective Than Monotherapy With Antiseizure Medicamentioning

confidence: 99%

Single-Target Versus Multi-Target Drugs Versus Combinations of Drugs With Multiple Targets: Preclinical and Clinical Evidence for the Treatment or Prevention of Epilepsy

Löscher¹

2021

Front. Pharmacol.

View full text Add to dashboard Cite

Rationally designed multi-target drugs (also termed multimodal drugs, network therapeutics, or designed multiple ligands) have emerged as an attractive drug discovery paradigm in the last 10–20 years, as potential therapeutic solutions for diseases of complex etiology and diseases with significant drug-resistance problems. Such agents that modulate multiple targets simultaneously are developed with the aim of enhancing efficacy or improving safety relative to drugs that address only a single target or to combinations of single-target drugs. Although this strategy has been proposed for epilepsy therapy >25 years ago, to my knowledge, only one antiseizure medication (ASM), padsevonil, has been intentionally developed as a single molecular entity that could target two different mechanisms. This novel drug exhibited promising effects in numerous preclinical models of difficult-to-treat seizures. However, in a recent randomized placebo-controlled phase IIb add-on trial in treatment-resistant focal epilepsy patients, padsevonil did not separate from placebo in its primary endpoints. At about the same time, a novel ASM, cenobamate, exhibited efficacy in several randomized controlled trials in such patients that far surpassed the efficacy of any other of the newer ASMs. Yet, cenobamate was discovered purely by phenotype-based screening and its presumed dual mechanism of action was only described recently. In this review, I will survey the efficacy of single-target vs. multi-target drugs vs. combinations of drugs with multiple targets in the treatment and prevention of epilepsy. Most clinically approved ASMs already act at multiple targets, but it will be important to identify and validate new target combinations that are more effective in drug-resistant epilepsy and eventually may prevent the development or progression of epilepsy.

show abstract

Innovative micellar-UPLC approach for concomitant determination of favipiravir and remdesivir with four co-administered cardiovascular drugs in their pharmaceuticals and spiked plasma: Greenness and whiteness assessment

Sayed,

Mohamed,

Shalaby

et al. 2023

Microchemical Journal

View full text Add to dashboard Cite

Fixed dose combinations: A formulary decision guide

Cited by 6 publications

References 31 publications

Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review

Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review

Single-Target Versus Multi-Target Drugs Versus Combinations of Drugs With Multiple Targets: Preclinical and Clinical Evidence for the Treatment or Prevention of Epilepsy

Innovative micellar-UPLC approach for concomitant determination of favipiravir and remdesivir with four co-administered cardiovascular drugs in their pharmaceuticals and spiked plasma: Greenness and whiteness assessment

Contact Info

Product

Resources

About